Experts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.
|Videos|March 14, 2011
Dr. Alter on 2011 ASCO GU Prostate Cancer Findings
Author(s)Robert S. Alter, MD
Robert S. Alter, M.D. Co-chief, Urologic Oncology, John Theurer Cancer Center, on prostate cancer research that was presented at the 2011 ASCO Genitourinary meeting.
Advertisement
Robert S. Alter, M.D. Co-chief, Urologic Oncology, John Theurer Cancer Center, on prostate cancer research that was presented at the 2011 ASCO Genitourinary meeting.
Advertisement
Related to this article
A dual antigen–targeted T-cell engager doublet produced durable PSA responses in late-line metastatic castration-resistant prostate cancer.
David VanderWeele, MD, PhD, reviews where lutetium Lu 177 vipivotide tetraxetan fits across metastatic prostate cancer, how to select and manage patients, and the new radionuclides, targeting molecules, and antigens under investigation.
Longer follow-up of CAPItello-281 showed capivasertib plus abiraterone extended survival in PTEN-deficient hormone-sensitive prostate cancer.
Lutetium Lu 177 vipivotide tetraxetan showed a median overall survival of 13.1 months in the French PSMA-REACH mCRPC cohort.
The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The top 5 OncLive TV videos of the week cover insights in endometrial cancer, mCRPC, germ cell tumors, melanoma, and HNSCC.
Advertisement
Advertisement
Trending on OncLive
1
Mo-Rez Responses Span B7-H4 Expression Levels in Platinum-Resistant Ovarian Cancer in BEHOLD-1 Biomarker Analysis
2
Genomic Testing, Toxicity, and Sequencing Shape Treatment Decisions in Advanced Prostate Cancer
3
FDA Approves Pimicotinib for Symptomatic TGCT
4
Dr Natsuhara on Treatment Advances and Research Considerations in TNBC
5